Brian K. Kaspar
Corporate Officer/Principal at The Ohio State University College of Medicine
Brian K. Kaspar active positions
| Companies | Position | Start | End |
|---|---|---|---|
| The Ohio State University College of Medicine | Corporate Officer/Principal | - | - |
Career history of Brian K. Kaspar
Former positions of Brian K. Kaspar
| Companies | Position | Start | End |
|---|---|---|---|
| AVEXIS INC | Director/Board Member | - | 2019-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2019-04-30 | |
Milo Biotechnology LLC
 Milo Biotechnology LLC BiotechnologyHealth Technology Milo Biotechnology LLC develops novel therapies based on follistatin, a protein that increases muscle mass and strength. The firm is targeting rare neuromuscular diseases, initiating a phase I/II clinical trial in Becker muscular dystrophy and inclusion body myositis. The company was founded by Al Hawkins and Brian K. Kaspar in January 2012 and is headquartered in Cleveland, OH. | Founder | 2011-12-31 | - |
Training of Brian K. Kaspar
| University of Illinois | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Statistics
International
| United States | 6 |
Operational
| Founder | 1 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Milo Biotechnology LLC
Milo Biotechnology LLC BiotechnologyHealth Technology Milo Biotechnology LLC develops novel therapies based on follistatin, a protein that increases muscle mass and strength. The firm is targeting rare neuromuscular diseases, initiating a phase I/II clinical trial in Becker muscular dystrophy and inclusion body myositis. The company was founded by Al Hawkins and Brian K. Kaspar in January 2012 and is headquartered in Cleveland, OH. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Stock Market
- Insiders
- Brian K. Kaspar
- Experience
